Known targets — ChEMBL curated mechanism
MMP1MMP13MMP7MMP8polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Mandelic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.78 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.78 |
| ▸ | CES2 | O00748 | 1/20 | 0.52 |
| ▸ | CES1 | P23141 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | NAAA | Q02083 | 2/20 | 0.49 |
| ▸ | SRC | P12931 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mandelic Acid SCHEMBL28154998 | 0.93 | LMNA (0.82) | LMNAMAPK1CES2CES1HPGD | |
| Mandelic Acid SCHEMBL2689215 | 0.89 | LMNA (0.75) | LMNAMAPK1CES2CES1HPGD | |
| Mandelic Acid SCHEMBL28014619 | 0.89 | LMNA (0.75) | LMNAMAPK1CES2CES1HPGD | |
| Mandelic Acid SCHEMBL28803140 | 0.89 | LMNA (0.82) | LMNAMAPK1CES2CES1HPGD | |
| Mandelic Acid SCHEMBL26611028 | 0.89 | LMNA (0.82) | LMNAMAPK1CES2CES1HPGD | |
| Mandelic Acid SCHEMBL7279536 | 0.89 | LMNA (0.90) | LMNAMAPK1CES2CES1HPGD | |
| Mandelic Acid SCHEMBL5313046 | 0.89 | LMNA (1.00) | LMNAMAPK1CES2CES1HPGD | |
| Mandelic Acid SCHEMBL165161 | 0.89 | LMNA (1.00) | LMNAMAPK1CES2CES1HPGD | |
| Mandelic Acid SCHEMBL21647917 | 0.89 | LMNA (1.00) | LMNAMAPK1CES2CES1HPGD | |
| Mandelic Acid SCHEMBL29777368 | 0.89 | LMNA (1.00) | LMNAMAPK1CES2CES1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021047166-A1 | METHOD FOR SYNTHESIZING TRANYLCYPROMINE INTERMEDIATE | 凯特立斯（深圳）科技有限公司 | 2021-03-18 | — | — | WO | disclosed |
| CN-109485634-A | A kind of preparation method of S- (+) duloxetine hydrochloride intermediate | 成都倍特药业有限公司 | 2019-03-19 | — | — | CN | disclosed |
| CN-104672141-B | Internal-(14S)-3-methoxy group-17-methyl morphinan picrate and preparation method and application thereof | 浙江普洛康裕制药有限公司 | 2017-02-15 | — | — | CN | disclosed |
| US-8957087-B2 | Heterocyclic substituted acardite derivate and application thereof | Jiangsu Provincial Institute of Materia Medica Co., Ltd. (CN) | 2015-02-17 | — | — | US | disclosed |
| EP-2428506-B1 | HETEROCYCLIC SUBSTITUTED ACARDITE DERIVATES AND USE THEREOF | NANJING LUYESIKE PHARMACEUTICAL CO LTD (CN) | 2014-03-05 | — | — | EP | disclosed |
| EP-2428506-A1 | HETEROCYCLIC SUBSTITUTED ACARDITE DERIVATES AND USE THEREOF | Jiangsu Provincial Institute Of Materia Medica Co. (CN) | 2012-03-14 | — | — | EP | disclosed |
| US-20120053192-A1 | Heterocyclic Substituted Acardite Derivate and Application Thereof | NANJING LUYESIKE PHARMACEUTICAL CO., LTD. (CN) | 2012-03-01 | — | — | US | disclosed |
| EP-0504349-A4 | BIOCONVERSIONS CATALYZED BY THE TOLUENE MONOOXYGENASE OF -I(PSEUDOMONAS MENDOCINA) KR-1 | AMGEN INC (US) | 1994-08-17 | — | — | EP | disclosed |
| EP-0504349-A1 | BIOCONVERSIONS CATALYZED BY THE TOLUENE MONOOXYGENASE OF $i(PSEUDOMONAS MENDOCINA) KR-1 | AMGEN INC. (US) | 1992-09-23 | — | — | EP | disclosed |
| WO-1992006208-A1 | BIOCONVERSIONS CATALYZED BY THE TOLUENE MONOOXYGENASE OF PSEUDOMONAS MENDOCINA KR-1 | AMGEN INC. (US) | 1992-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053192-A1 | Heterocyclic Substituted Acardite Derivate and Application Thereof | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, IDH1, CA7 | LMNA 4255/4885MAPK1 3213/4885CES2 717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.